

Supplemental Table S1: Model parameters

Parameter	Abbreviation	Value (%CV)	Units	Source
Anetumab ravtansine clearance	CL _{ADC}	5.6E-04 (3.2%)	L/hr*kg	Model Fitting
Anetumab ravtansine distribution clearance	CLD _{ADC}	8.7E-04 (20%)	L/hr*kg	Model Fitting
Anetumab ravtansine central volume	V1 _{ADC}	5.3E-02 (3.9%)	L/kg	Model Fitting
Anetumab ravtansine peripheral volume	V2 _{ADC}	5.4E-02 (11%)	L/kg	Model Fitting
Human glomerulus filtration rate	GFR	1.1E-01	L/hr*kg	[1]
DM4 volume of distribution	V _{DM4}	3.6E-01 (11%)	L/kg	Model Fitting
DM4 metabolism clearance	CL _{met}	2.3E-01 (13%)	L/hr*kg	Model Fitting
S-Methyl-DM4 clearance	CL _{SMeDM4}	4.2E-02 (13%)	L/hr*kg	Model Fitting
Association rate constant sdAb:DM4	k _{on}	0.68	nM ⁻¹ hr ⁻¹	In-vitro
Dissociation rate constant sdAb:DM4	k _{off}	2.6	hr ⁻¹	In-vitro
Drug-to-antibody ratio	DAR	3.2	None	[2]
Anti-maytansinoid sdAb central volume	V1 _{sdAb}	4.1E-2	L/kg	[1]
Anti-maytansinoid sdAb peripheral volume	V2 _{sdAb}	9.2E-2	L/kg	[1]
Anti-maytansinoid sdAb distribution clearance	CLD _{sdAb}	5.5E-2	L/h*kg	[1]

1. Hoefman S, Ottevaere I, Baumeister J and Sargentini-Maier ML (2015) Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®. *Antibodies* 4:141-156.
2. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle F-D, Müller-Tiemann B, Kreft B and Ziegelbauer K (2014) Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect. *Molecular Cancer Therapeutics* 13:1537-1548. doi: 10.1158/1535-7163.mct-13-0926